Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_4
5
45%
Ph phase_1
1
9%
Ph phase_2
2
18%
Ph not_applicable
3
27%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 4Post-market surveillance
5(45.5%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)
Other(1)

Detailed Status

Completed8
Not yet recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 22 (18.2%)
Phase 45 (45.5%)
N/A3 (27.3%)

Trials by Status

not_yet_recruiting19%
unknown19%
completed873%
terminated19%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
11